Tags

Type your tag names separated by a space and hit enter

Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis.
Blood 2014; 123(23):3567-73Blood

Abstract

Due to disease rarity, there is limited information regarding the optimal therapy and outcome for patients with advanced-stage nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Forty-two patients with NLPHL by the Revised European-American Lymphoma/World Health Organization classification with advanced-stage disease were identified and paired 1:2 with a matched control with classical Hodgkin lymphoma (CHL) matched by age, gender, stage, decade of diagnosis, and treatment received. The median follow-up was 11.3 years (range, 1.9 to 35.5 years) for NLPHL patients and 10.7 years (range, 1.6 to 26.3 years) for CHL patients. The majority received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-like chemotherapy. Although the 10-year overall survival (OS) (P = .579) and HL freedom from treatment failure (HL-FFTF) were similar between NLPHL and CHL patients (75% vs 73%; P = .610), the time to progression (TTP), which also includes the development of secondary aggressive lymphoma, was inferior in NLPHL (10-year, 63% vs 73%; P = .040). Splenic involvement was associated with an inferior 10-year TTP in patients treated with ABVD (48% vs 71%; P = .049) and an increased cumulative incidence of secondary aggressive lymphoma (P = .014) providing a rationale for further evaluation of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with rituximab in NLPHL.

Authors+Show Affiliations

Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada;Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada;Cancer Surveillance and Outcomes, Population Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada;Oncology Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia; and.Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada;Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada;Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada;Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada;Centre for Lymphoid Cancer and Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada.Centre for Lymphoid Cancer and Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada.Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada;

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24713929

Citation

Xing, Katharine H., et al. "Advanced-stage Nodular Lymphocyte Predominant Hodgkin Lymphoma Compared With Classical Hodgkin Lymphoma: a Matched Pair Outcome Analysis." Blood, vol. 123, no. 23, 2014, pp. 3567-73.
Xing KH, Connors JM, Lai A, et al. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood. 2014;123(23):3567-73.
Xing, K. H., Connors, J. M., Lai, A., Al-Mansour, M., Sehn, L. H., Villa, D., ... Savage, K. J. (2014). Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood, 123(23), pp. 3567-73. doi:10.1182/blood-2013-12-541078.
Xing KH, et al. Advanced-stage Nodular Lymphocyte Predominant Hodgkin Lymphoma Compared With Classical Hodgkin Lymphoma: a Matched Pair Outcome Analysis. Blood. 2014 Jun 5;123(23):3567-73. PubMed PMID: 24713929.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. AU - Xing,Katharine H, AU - Connors,Joseph M, AU - Lai,Anky, AU - Al-Mansour,Mubarak, AU - Sehn,Laurie H, AU - Villa,Diego, AU - Klasa,Richard, AU - Shenkier,Tamara, AU - Gascoyne,Randy D, AU - Skinnider,Brian, AU - Savage,Kerry J, Y1 - 2014/04/08/ PY - 2014/4/10/entrez PY - 2014/4/10/pubmed PY - 2014/8/15/medline SP - 3567 EP - 73 JF - Blood JO - Blood VL - 123 IS - 23 N2 - Due to disease rarity, there is limited information regarding the optimal therapy and outcome for patients with advanced-stage nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Forty-two patients with NLPHL by the Revised European-American Lymphoma/World Health Organization classification with advanced-stage disease were identified and paired 1:2 with a matched control with classical Hodgkin lymphoma (CHL) matched by age, gender, stage, decade of diagnosis, and treatment received. The median follow-up was 11.3 years (range, 1.9 to 35.5 years) for NLPHL patients and 10.7 years (range, 1.6 to 26.3 years) for CHL patients. The majority received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-like chemotherapy. Although the 10-year overall survival (OS) (P = .579) and HL freedom from treatment failure (HL-FFTF) were similar between NLPHL and CHL patients (75% vs 73%; P = .610), the time to progression (TTP), which also includes the development of secondary aggressive lymphoma, was inferior in NLPHL (10-year, 63% vs 73%; P = .040). Splenic involvement was associated with an inferior 10-year TTP in patients treated with ABVD (48% vs 71%; P = .049) and an increased cumulative incidence of secondary aggressive lymphoma (P = .014) providing a rationale for further evaluation of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with rituximab in NLPHL. SN - 1528-0020 UR - https://www.unboundmedicine.com/medline/citation/24713929/Advanced_stage_nodular_lymphocyte_predominant_Hodgkin_lymphoma_compared_with_classical_Hodgkin_lymphoma:_a_matched_pair_outcome_analysis_ L2 - http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=24713929 DB - PRIME DP - Unbound Medicine ER -